PharmaCyte Biotech, Inc. (Nasdaq: PMCB), an SEC filer in Biological Products, (No Diagnostic Substances), closed at $0.52, -4.7%, on 2026-08-28, with a market cap of $6M as of 2026-08-27, a trailing P/E of 0.2 and a return on equity of 77.1%. Institutional ownership, earnings history and filed financials are on the tabs below.
Returns use ADJUSTED closes (splits + dividends).
Volume as VALUE TRADED — close × volume, in USD.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | PMCB | SPY | Δ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 · ytd | +13.1% | −15.7% | −3.6% | +8.5% | +15.6% | −7.7% | −25.2% | −10.6% | — | — | — | — | −28.9% | +13.4% | −42.3pp |
| 2025 | +2.2% | +9.9% | −29.1% | −0.8% | −17.3% | +6.3% | −6.4% | −7.9% | +3.3% | −4.1% | −16.8% | −6.4% | −53.9% | +17.7% | −71.6pp |
| 2024 | +1.4% | −4.1% | +12.9% | −10.5% | −7.5% | +0.0% | +0.0% | −21.9% | +24.8% | −5.2% | −5.5% | −8.2% | −27.3% | +24.9% | −52.2pp |
| 2023 | −1.4% | +3.8% | −3.0% | +0.3% | +7.9% | −9.2% | −7.0% | −7.9% | −14.3% | +1.0% | +6.6% | −4.4% | −26.3% | +26.2% | −52.5pp |
| 2022 | −14.4% | −0.5% | +8.0% | +1.3% | −1.3% | −2.6% | +6.7% | +10.0% | −8.7% | +22.5% | +2.7% | −3.0% | +17.2% | −18.2% | +35.4pp |
| 2021 | +168.7% | +55.6% | −38.9% | +3.5% | −28.2% | −15.0% | −28.3% | −71.9% | −5.9% | −11.0% | −8.2% | −3.5% | −75.9% | +28.7% | −104.7pp |
| 2020 | +48.1% | −16.7% | −40.0% | −16.3% | −20.4% | +14.7% | −37.7% | −16.8% | −16.0% | −11.0% | −32.6% | +11.7% | −83.5% | +18.3% | −101.8pp |
| 2019 | +13.0% | +27.8% | −9.0% | −15.6% | −7.1% | +2.4% | +1.3% | −12.4% | +6.4% | −4.9% | −1.4% | +17.4% | +9.5% | +31.2% | −21.8pp |
| 2018 | +28.9% | −21.4% | −6.5% | +2.3% | −3.9% | +31.6% | −18.0% | −6.3% | +9.0% | −9.1% | −7.3% | −23.2% | −33.7% | −4.6% | −29.1pp |
| 2017 | −23.1% | −2.9% | −11.4% | −20.9% | −16.6% | −13.7% | +37.3% | −22.1% | −3.3% | −7.8% | −10.3% | +16.2% | −62.5% | +21.7% | −84.2pp |
Month-end over prior month-end; a blank cell is no return.
Basis. PMCB and SPY are on DIFFERENT bases — one includes dividends, the other doesn't, so the Δ column flatters the dividend-including side.
End-of-day closes; a “ytd” or “part” year is not a full year.
| Month | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Years ⓘ | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 16 | 16 | 16 |
| Positive ⓘ | 63% | 53% | 35% | 59% | 29% | 29% | 29% | 12% | 31% | 50% | 25% | 31% |
| Median | +7.6% | +3.8% | −6.5% | +1.3% | −5.7% | −7.7% | −5.8% | −12.4% | −5.6% | −0.2% | −7.9% | −5.4% |
| Best | +168.7% | +133.2% | +49.2% | +32.0% | +138.6% | +31.6% | +40.7% | +14.3% | +24.8% | +122.2% | +75.7% | +129.1% |
| Worst | −40.2% | −32.6% | −42.1% | −20.9% | −28.2% | −24.5% | −37.7% | −71.9% | −19.2% | −11.0% | −32.6% | −46.5% |
| vs SPY ⓘ | +2.4pp | +2.5pp | −6.7pp | −1.3pp | −6.3pp | −6.7pp | −8.2pp | −10.7pp | −3.1pp | −0.8pp | −9.8pp | −7.3pp |
199 monthly observations · 2010–2026 · benchmark SPY
